Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Website: boltbio.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 86.1%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -786.7%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2 135.5% higher than minimum and 6.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -29.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: BOLT
Share price, USD:  (0.0%)6.55
year average price 3.93  


year start price 0.48 2025-02-12

min close price 0.29 2025-05-16

max close price 6.98 2026-01-15

current price 6.55 2026-02-11
Common stocks: 38 339 697

Dividend Yield:  0.0%
EV / Sales: 17.9x
Margin (EBITDA LTM / Revenue): -786.7%
Fundamental value created in LTM:
Market Cap ($m): 251
Net Debt ($m): 18
EV (Enterprise Value): 269
Price to Book: 7.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-14zacks.com

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

2024-09-03prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

2024-09-03accesswire.com

The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit

2024-09-03prnewswire.com

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

2024-09-02businesswire.com

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

2024-09-01accesswire.com

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

2024-08-31prnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

2024-08-30prnewswire.com

BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit

2024-08-30accesswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

2024-08-29globenewswire.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-14 2024-11-12 2024-08-13 2024-05-14 2023-11-09 2023-08-07 2023-05-11 2022-11-10 2022-08-10
acceptedDate 2025-11-12 16:08:06 2025-08-14 16:09:03 2025-03-24 16:26:40 2024-11-12 16:14:15 2024-08-13 16:10:05 2024-05-14 16:14:40 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47 2022-03-30 16:10:31 2021-03-31 16:06:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 2M 2M 8M 1M 1M 5M 8M 3M 1M 2M 6M 2M 1M 1M 231 000
costOfRevenue 290 000 0 0 0 15M 458 000 62M 462 000 1M 0 73M 0 0 76M 40M
grossProfit 2M 2M 8M 1M -14M 5M -54M 2M 244 000 2M -67M 2M 1M -74M -40M
grossProfitRatio 0.866 1 1 -11.104 0.913 0.817 0.17 1 1 1
researchAndDevelopmentExpenses 6M 7M 57M 14M 15M 16M 62M 15M 16M 15M 73M 19M 19M 76M 40M
generalAndAdministrativeExpenses 0 4M 18M 4M 5M 6M 23M 6M 6M 6M 23M 5M 6M 18M 9M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 4M 18M 4M 5M 6M 23M 6M 6M 6M 23M 5M 6M 18M 9M
otherExpenses 0 0 5M 0 4M 5M -62M 0 0 0 -73M 0 0 -76M -40M
operatingExpenses 10M 11M 81M 18M 20M 22M 23M 21M 21M 20M 23M 24M 24M 18M 9M
costAndExpenses 10M 11M 81M 18M 24M 22M 84M 21M 21M 20M 96M 24M 24M 94M 49M
interestIncome 477 000 599 000 5M 1M 1M 2M 7M 2M 2M 1M 2M 587 000 395 000 281 000 199 000
interestExpense 0 0 0 0 0 0 0 0 0 -1M 0 587 000 395 000 0 0
depreciationAndAmortization 290 000 347 000 2M 440 000 457 000 458 000 2M 462 000 458 000 467 000 2M 439 000 408 000 1M 611 000
ebitda -7M -9M -66M -16M -19M -17M -74M -18M -19M -18M -89M -22M -22M -92M -49M
ebitdaratio -3.16 -4.913 -14.025 -14.569 -3.154 -7.193 -13.52 -9.829 -10.373 -15.693
operatingIncome -8M -9M -73M -16M -23M -17M -76M -18M -20M -18M -90M -22M -23M -93M -49M
operatingIncomeRatio -3.551 -5.105 -14.411 -17.723 -3.241 -7.193 -13.839 -10.085 -10.58 -16.553
totalOtherIncomeExpensesNet 559 000 649 000 10M 1M 1M 6M 7M 2M 2M 1M 2M 587 000 395 000 -6M -12M
incomeBeforeTax -7M -9M -63M -15M -21M -11M -69M -16M -18M -17M -88M -22M -23M -99M -61M
incomeBeforeTaxRatio -3.294 -4.746 -13.301 -16.624 -2.05 -6.431 -12.601 -9.299 -10.303 -16.27
incomeTaxExpense 0 0 0 0 0 414 724 0 -462 000 0 -1M 0 -587 000 0 0 0
netIncome -7M -9M -63M -15M -21M -11M -69M -16M -18M -16M -88M -21M -23M -99M -61M
netIncomeRatio -3.294 -4.746 -13.301 -16.624 -2.05 -6.431 -12.601 -8.513 -10.025 -16.27
eps -3.722 -4.46 -1.65 -0.4 -0.56 -0.28 -1.83 -0.43 -0.48 -0.41 -2.3 -0.57 -0.61 -2.79 -1.99
epsdiluted -3.722 -4.46 -0.4 -0.56 -0.28 -0.43 -0.48 -0.41 -0.57 -0.61
weightedAverageShsOut 2M 2M 38M 38M 38M 38M 38M 38M 38M 38M 37M 37M 37M 37M 36M
weightedAverageShsOutDil 2M 2M 38M 38M 38M 38M 38M 38M 38M 38M 37M 37M 37M 37M 36M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-21 2023-03-29 2022-03-30 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 5M 7M 2M 281 000 199 000
ebit -68M -76M -90M -93M -49M
nonOperatingIncomeExcludingInterest -5M 0 0 0 0
netIncomeFromContinuingOperations -63M -69M -88M -99M -61M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -63M -69M -88M -99M -61M
epsDiluted -1.65 -1.83 -2.3 -2.79 -1.99

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-14 2024-11-12 2024-08-13 2024-05-14 2023-11-09 2023-08-07 2023-05-11 2022-11-10 2022-08-10
acceptedDate 2025-11-12 16:08:06 2025-08-14 16:09:03 2025-03-24 16:26:40 2024-11-12 16:14:15 2024-08-13 16:10:05 2024-05-14 16:14:40 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47 2022-03-30 16:10:31 2021-03-31 16:06:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 18M 10M 7M 9M 6M 4M 11M 9M 13M 15M 9M 11M 23M 27M 6M
shortTermInvestments 14M 25M 40M 44M 67M 87M 91M 111M 112M 112M 160M 161M 154M 159M 17M
cashAndShortTermInvestments 32M 35M 47M 54M 74M 91M 102M 120M 126M 126M 169M 171M 176M 186M 23M
netReceivables 0 0 1M 0 0 900 000 0 3M 2M 0 0 0 0 200 000 0
inventory 0 0 0 0 0 0 0 -3M -2M 0 0 0 0 0 0
otherCurrentAssets 4M 4M 1M 3M 3M 3M 4M 6M 5M 5M 4M 4M 5M 3M 0
totalCurrentAssets 36M 38M 51M 57M 77M 95M 106M 125M 131M 132M 173M 175M 181M 189M 25M
propertyPlantEquipmentNet 21M 22M 25M 20M 22M 23M 24M 25M 26M 27M 29M 30M 29M 31M 16M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 7M 14M 23M 31M 24M 23M 26M 22M 31M 45M 24M 38M 47M 87M 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 1M 1M 1M 1M 2M 2M 4M 3M 3M 3M 3M 3M 3M 1M 5M
totalNonCurrentAssets 29M 37M 49M 52M 48M 48M 54M 50M 60M 75M 55M 71M 79M 119M 21M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 65M 75M 100M 109M 124M 143M 160M 175M 191M 206M 228M 246M 260M 308M 47M
accountPayables 2M 2M 2M 1M 3M 2M 3M 4M 3M 2M 4M 4M 3M 4M 2M
shortTermDebt 3M 3M 0 3M 6M 3M 0 3M 3M 2M 0 2M 2M 3M 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 3M 3M 2M 2M 2M 2M 2M 2M 2M 2M 3M 4M 3M 2M
otherCurrentLiabilities 4M 5M 4M 12M 7M 10M 7M 10M 10M 10M 5M 15M 10M 7M 4M
totalCurrentLiabilities 10M 12M 16M 18M 18M 17M 20M 19M 18M 16M 23M 24M 19M 21M 11M
longTermDebt 21M 22M 0 15M 16M 17M 0 18M 19M 20M 0 21M 21M 0 0
deferredRevenueNonCurrent 0 3M 4M 4M 5M 5M 9M 10M 12M 13M 13M 12M 13M 14M 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 2M 133 000 0 0 0 -1 43 000 43 000 43 000 43 000 42 000 24M 200 000 210 000 131M
totalNonCurrentLiabilities 23M 24M 27M 19M 20M 22M 27M 28M 31M 32M 33M 33M 34M 36M 140M
otherLiabilities 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 24M 25M 18M 19M 17M 20M 21M 21M 22M 23M 23M 23M 22M 11M
totalLiabilities 33M 37M 42M 37M 38M 39M 47M 47M 49M 48M 56M 57M 52M 58M 151M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 1000 1000 1000 1000 1000 1000 0 0 0 0 0 0
retainedEarnings -454M -447M -427M -411M -396M -375M -364M -346M -330M -312M -295M -275M -253M -207M -108M
accumulatedOtherComprehensiveIncomeLoss -10000 -6000 97 000 0 -44 000 -36 000 37 000 -174 000 -229 000 -235 000 -919 000 -2M -2M -321 000 0
othertotalStockholdersEquity 486M 486M 483M 482M 479M 475M 472M 470M 465M 463M
totalStockholdersEquity 32M 39M 57M 72M 86M 104M 113M 128M 142M 158M 172M 188M 208M 250M -105M
totalEquity 32M 39M 57M 72M 86M 104M 113M 128M 142M 158M 172M 188M 208M 250M -105M
totalLiabilitiesAndStockholdersEquity 65M 75M 109M 124M 143M 175M 191M 206M 246M 260M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 65M 75M 100M 109M 124M 143M 160M 175M 191M 206M 228M 246M 260M 308M 47M
totalInvestments 21M 39M 63M 75M 91M 110M 118M 132M 144M 156M 184M 199M 201M 246M 17M
totalDebt 24M 24M 25M 18M 19M 20M 20M 21M 21M 22M 23M 23M 23M 24M 11M
netDebt 6M 15M 18M 9M 13M 15M 9M 12M 8M 7M 13M 13M 276 000 -3M 5M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-21 2023-03-29 2022-03-30 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 1M 0 0 200 000 0
prepaids 1M 0 0 0 3M
totalPayables 2M 3M 4M 4M 2M
otherPayables 0 0 0 0 0
accruedExpenses 5M 6M 10M 5M 3M
capitalLeaseObligationsCurrent 2M 3M 2M 0 2M
capitalLeaseObligationsNonCurrent 23M 17M 20M 22M 9M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 485M 477M 468M 457M 3M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT BOLT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-14 2024-11-12 2024-08-13 2024-05-14 2023-11-09 2023-08-07 2023-05-11 2022-11-10 2022-08-10
acceptedDate 2025-11-12 16:08:06 2025-08-14 16:09:03 2025-03-24 16:26:40 2024-11-12 16:14:15 2024-08-13 16:10:05 2024-05-14 16:14:40 2024-03-21 16:10:43 2023-11-09 16:10:35 2023-08-07 16:08:50 2023-05-11 16:11:18 2023-03-29 16:15:59 2022-11-10 16:17:32 2022-08-10 16:09:47 2022-03-30 16:10:31 2021-03-31 16:06:10
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -7M -9M -63M -15M -21M -11M -69M -16M -18M -17M -88M -22M -23M -99M -61M
depreciationAndAmortization 290 000 347 000 2M 440 000 457 000 458 000 2M 462 000 458 000 467 000 2M 439 000 408 000 1M 611 000
deferredIncomeTax 0 0 0 0 0 0 0 -1M -1M 0 0 0 0 3M 34 000
stockBasedCompensation 407 000 625 000 7M 1M 3M 2M 9M 2M 2M 2M 10M 2M 2M 9M 1M
changeInWorkingCapital -4M -2M -8M 7M 2M -8M -10M -3M 518 000 -9M -3M 5M -2M 21M -2M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 -4M -3M 0 0 -7M 3M 0 -3M 7M 3M
otherWorkingCapital -4M -2M -8M 7M 2M -8M -6M -3M 518 000 -3M -6M 5M -819 000 14M -5M
otherNonCashItems 506 000 454 000 1M -7M -3000 3M -2M 744 000 731 000 -133 000 3M 644 000 894 000 9M 14M
netCashProvidedByOperatingActivities -10M -10M -61M -14M -16M -17M -70M -17M -15M -23M -77M -13M -21M -57M -47M
investmentsInPropertyPlantAndEquipment -72 000 0 -41 000 -41 000 0 0 -206 000 -165 000 -32 000 -3000 -2M -735 000 -429 000 -2M -3M
acquisitionsNet 0 0 148 000 0 0 0 0 -13M -14M 0 -60M 0 0 230M 17M
purchasesOfInvestments -2M -14M -89M -20M -32M -23M -165M -36M -54M -43M -181M -48M -31M -313M -33M
salesMaturitiesOfInvestments 20M 25M 146M 37M 50M 33M 236M 49M 67M 72M 241M 50M 31M 84M 16M
otherInvestingActivites 0 0 148 000 0 10M 13M 14M 0 0 0
netCashUsedForInvestingActivites 18M 11M 17M 18M 10M 13M 14M 29M 1M -868 000
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 14 000 0 0 79 000 0 0 147 000 0 0 252 000
commonStockRepurchased 0 0 0 -79 000 79 000 0 0 0 141 000 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -14 000 14 000 0 0 0 0 -141 000 0 0 0
netCashUsedProvidedByFinancingActivities 0 14 000 0 79 000 0 0 147 000 0 0 252 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 -14M 0 0 0 0 0 0
netChangeInCash 8M 1M -4M 5M 2M -7M 2M -4M -1M 6M -18M -12M -21M 22M -28M
cashAtEndOfPeriod 19M 11M 9M 11M 6M 4M 13M 11M 15M 16M 11M 12M 24M 29M 7M
cashAtBeginningOfPeriod 10M 10M 13M 6M 4M 11M 11M 15M 16M 11M 29M 24M 46M 7M 35M
operatingCashFlow -10M -10M -61M -14M -16M -17M -70M -17M -15M -23M -77M -13M -21M -57M -47M
capitalExpenditure -72 000 0 -41 000 -41 000 0 0 -206 000 -165 000 -32 000 -3000 -2M -735 000 -429 000 -2M -3M
freeCashFlow -10M -10M -61M -14M -16M -17M -70M -17M -15M -23M -78M -14M -21M -59M -51M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-21 2023-03-29 2022-03-30 2021-03-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 60M -230M -17M
netCashProvidedByInvestingActivities 58M 71M 58M -232M -21M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 108 000 253 000 503 000 311M 42M
netCommonStockIssuance 108 000 253 000 503 000 259M 294 000
commonStockIssuance 108 000 253 000 503 000 259M 294 000
netPreferredStockIssuance 0 0 0 52M 41M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 -2M
netCashProvidedByFinancingActivities 108 000 253 000 503 000 311M 40M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2024 q1
2024-05-17 ET (fiscal 2024 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-12 16:08 ET
Bolt Biotherapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-12 16:05 ET
Bolt Biotherapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-12 16:05 ET
Bolt Biotherapeutics, Inc. published news for 2025 q3
SEC form 10
2025-08-14 20:09 ET
Bolt Biotherapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:05 ET
Bolt Biotherapeutics, Inc. published news for 2025 q2
SEC form 8
2025-08-14 20:05 ET
Bolt Biotherapeutics, Inc. reported for 2025 q2
SEC form 10
2025-05-12 20:08 ET
Bolt Biotherapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-12 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2025 q1
SEC form 8
2025-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2025 q1
SEC form 8
2025-04-16 21:22 ET
Bolt Biotherapeutics, Inc. published news for 2025 q1
SEC form 8
2025-04-16 21:22 ET
Bolt Biotherapeutics, Inc. published news for 2025 q1
SEC form 10
2025-03-24 16:26 ET
Bolt Biotherapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-24 16:25 ET
Bolt Biotherapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-24 16:25 ET
Bolt Biotherapeutics, Inc. published news for 2024 q4
SEC form 10
2025-03-24 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2024 q4
SEC form 10
2024-11-12 16:14 ET
Bolt Biotherapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-12 16:09 ET
Bolt Biotherapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-12 16:09 ET
Bolt Biotherapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-13 16:10 ET
Bolt Biotherapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-13 16:08 ET
Bolt Biotherapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-13 16:08 ET
Bolt Biotherapeutics, Inc. reported for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-14 16:14 ET
Bolt Biotherapeutics, Inc. reported for 2024 q1
SEC form 10
2024-05-14 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-21 16:10 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2024-03-21 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-09 16:10 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-07 16:08 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-07 16:06 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-13 16:55 ET
Bolt Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-11 16:11 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:09 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:09 ET
Bolt Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-29 16:15 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-29 16:13 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-29 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q4
SEC form 8
2022-11-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q3
SEC form 8
2022-08-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q2
SEC form 8
2022-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Bolt Biotherapeutics, Inc. reported for 2022 q1
SEC form 8
2022-03-30 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q4
SEC form 8
2021-11-09 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q3
SEC form 8
2021-08-12 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q2
SEC form 8
2021-05-13 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Bolt Biotherapeutics, Inc. published news for 2021 q1